Editorial
Are We Overstudying Biosimilars? Re‐Centering Clinical Pharmacology in the Demonstration of Similarity
Clinical Pharmacology in Drug Development · 2026-04 · 15 (4)
DOI: 10.1002/cpdd.70051 ↗Kurz gefasst
Editorial in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 01.04.2026. Verfasst von Amalia M Issa. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Issa, A. M. (2026). Are We Overstudying Biosimilars? Re‐Centering Clinical Pharmacology in the Demonstration of Similarity. Clinical Pharmacology in Drug Development, 15(4). https://doi.org/10.1002/cpdd.70051
Vancouver
Issa AM. Are We Overstudying Biosimilars? Re‐Centering Clinical Pharmacology in the Demonstration of Similarity. Clinical Pharmacology in Drug Development. 2026;15(4). doi:10.1002/cpdd.70051
BibTeX
@article{Issa2026,
author = {Issa, Amalia M},
title = {Are We Overstudying Biosimilars? Re‐Centering Clinical Pharmacology in the Demonstration of Similarity},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cpdd.70051}
}
EUVIMED